Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend?

NodeGuardian

2026-03-29 16:46:18

Abstract generation in progress

This article discusses whether Bristol Myers Squibb (BMY) is a good investment for its 4.4% dividend yield. While the company has a strong dividend track record, patent cliffs for key drugs like Eliquis and Opdivo and flat to declining revenue forecasts create significant uncertainty. The author recommends caution and suggests an index fund for dividends instead due to the potential for future dividend cuts or suspensions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes